INmune Bio, Inc. (INMB) AI Stock Analysis

INmune Bio, Inc. is a clinical-stage immunotherapy company headquartered in Boca Raton, Florida. Founded in 2015, the firm specializes in harnessing and reprogramming the innate immune system to develop treatments for cancer, Alzheimer's disease, and non-alcoholic steatohepatitis (NASH). Its clinical pipeline includes INKmune for relapse refractory ovarian carcinoma and high-risk myelodysplastic syndrome, INB03 for advanced cancers exhibiting elevated inflammation biomarkers, and XPro1595 for Alzheimer's disease. The company is also developing LivNate for NASH and Quellor for cytokine release syndrome and COVID-19 complications, supported by licensing collaborations with Xencor, Inc., Immune Ventures, LLC, University of Pittsburgh, and University College London.

INmune Bio generates early-stage revenue, which increased from $14,000 in FY2024 to $50,000 in FY2025, representing a 257.1% increase. Over a 5-year period from FY2020 to FY2025, revenue grew at a CAGR of 35.6%. Operating losses remain substantial due to research and development expenses, which totaled $20.7M in FY2025. INMB reported an annual net loss of -$45.9M and diluted EPS of -$1.19 for FY2025, with an operating margin of -61738.0%. For the trailing twelve months ended June 30, 2026, revenue stood at $0, net profit margin was 0.0%, and EPS was -$0.67.

As of June 30, 2026, INmune Bio held $18.4M in cash and short-term investments, total debt of $1.4M, and net cash of $17.0M. The company had a current ratio of 4.04 and a debt-to-equity ratio of 0.07 against shareholders' equity of $20.4M. For FY2025, operating cash flow was -$22.6M and free cash flow was -$23.6M, which included capital expenditures of $1.0M. Over 5 years, the company's share count expanded by 54.2%.

At a share price of $1.57 and a market capitalization of $43.6M, INMB trades at an enterprise value of $38.5M. The stock has a price-to-sales multiple of 760.3x, substantially above the 4.1x median of its US-listed Healthcare peers, and a price-to-book ratio of 2.7x. Over the past year, INMB shares dropped 15.1%, lagging the S&P 500 (SPY) return of 16.8%. Over a 5-year timeframe, the stock declined 91.6% compared to an 83.0% gain for SPY.

Wall Street coverage includes 2 Strong Buy ratings and 1 Buy rating. The mean price target is $7.00, representing an upside of 345.9% from the closing price of $1.57 on October 16, 2026. For the current fiscal year ending December 31, 2026, analysts forecast revenue of $0 and an EPS of -$0.55. For the next fiscal year, consensus estimates project $9.5M in revenue and an EPS of -$0.43. INMB has exceeded EPS estimates in 3 of the last 4 quarters, with the next earnings release scheduled for October 29, 2026.

This page is an AI-written research summary of INmune Bio, Inc. (INMB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: INMB income statement, INMB balance sheet, INMB key metrics, INMB analyst forecast, INMB chart. See the INMB stock overview for the latest quote and news.